NuGen Medical Devices Inc. (NGMD.V)
| Previous Close | 0.1000 |
| Open | 0.1050 |
| Bid | 0.1000 x N/A |
| Ask | 0.1050 x N/A |
| Day's Range | 0.0950 - 0.1050 |
| 52 Week Range | 0.0900 - 0.2550 |
| Volume | |
| Avg. Volume | 349,089 |
| Market Cap | 19.903M |
| Beta (5Y Monthly) | 2.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | May 28, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.NuGen Medical Devices Full Year 2023 Earnings: CA$0.056 loss per share (vs CA$0.062 loss in FY 2022)
NuGen Medical Devices ( CVE:NGMD ) Full Year 2023 Results Key Financial Results Net loss: CA$9.36m (loss widened by 68...
NewsfileNuGen Announces Debt Settlement and Amendments to Care4Pharma Share Purchase Agreement
Toronto, Ontario--(Newsfile Corp. - April 15, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") announces that it has agreed to settle an aggregate of €275,000 of indebtedness owed to Care4Pharma B.V. ("Care4Pharma"), an arm's length creditor (the "Creditor"), with respect to monies owed pursuant to the share purchase agreement between the Company and Care4Pharma dated June 30, 2021 (the "Share Purchase Agreement"), through the issuance of an aggregate of 2,000,000 ...
NewsfileNuGen Announces Completion of Product Training with Sol Millennium as European Markets Expand
Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of January 30th, 2024, Sol-Millennium Medical Inc.'s ("Sol-M") global sales & marketing team has now completed their in-depth clinical training of NuGen's needle-free InsuJet™ medical device for sales and marketing throughout Europe. Louise Cresswell, NuGen's
